e6005
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01179880)
Timeline
Indications
Studied for
Mechanism of action
PDE4A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- e6005
- e6005
- e6005
- methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate
- rvt-501
- rvt-501
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02950922 | Phase 2 | Nov 1, 2016 | Roivant Sciences, Inc. |
| NCT02094235 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2014 | Eisai |
| NCT01461941 | Phase 2 | Dec 1, 2011 | Eisai |
| NCT01179880 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2010 | Eisai |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 3 | 3 | 1 | 2010 |
| Roivant Sciences, Inc. | For profit | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1